Baird Medical Investment
Baird Medical Investment's revenue fell 39.1% to $22 million in fiscal 2025. Its operating margin was −113.7%, down from 41.4% a year earlier. Free cash flow was −$1 million. The diluted share count rose 27.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2022 to 2024, earnings per share grew 7.9% a year and net income fell 1.2% a year, as the share count fell by 15%. Baird Medical Investment then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 2 | 2 | 3 | 0 |
| Debt incl. finance leases | — | 2 | 4 | 9 |
| Net debt (negative means net cash) | — | 1 | 2 | 8 |
| Net debt to EBITDA | — | 0.1x | 0.1x | — |
| Debt to equity | — | 0.1x | 0.1x | 0.3x |
| Interest coverage | 45.5x | 41.7x | 26.6x | −34.8x |
| Current ratio | — | 2.1x | 1.8x | 1.7x |
| Quick ratio | — | 2.0x | 1.7x | 1.7x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 1 of 9 |
| Rule of 40 | −22.0% | −7.0% | −45.3% |
| Altman Z'' | 6.46 | 5.79 | 0.48 |
| Accruals ratio | — | 27.9% | −35.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | — | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | — | Fail | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | 1 of 9 |
Compare
Put Baird Medical Investment side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Baird Medical Investment | FY25 | −39.1% | −113.7% | −6.2% | −50.0% | — | 1 | |
| DarioHealth | FY25 | −17.3% | −163.9% | −116.7% | — | — | — | Compare |
| Lifeward | FY25 | −14.1% | −89.3% | −76.4% | — | — | — | Compare |
| Jin Medical International | FY25 | −12.0% | 2.9% | −18.0% | — | — | — | Compare |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 35 | 32 | 37 | 22 |
| Revenue growth | — | −10.3% | 17.7% | −39.1% |
| Gross profit | 28 | 27 | 33 | 19 |
| Research and development | 4 | 4 | 6 | 20 |
| Operating income | 14 | 12 | 15 | −26 |
| Net income | 13 | 10 | 12 | −27 |
| Diluted EPS (US$) | 0.49 | 0.51 | 0.57 | −0.98 |
| Diluted shares (millions) | 26 | 21 | 22 | 28 |
| Cash flow | ||||
| Cash from operations | 0 | −1 | −6 | −1 |
| Capital expenditure | 6 | 3 | 3 | 0 |
| Free cash flow | −5 | −4 | −9 | −1 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 0 | 18 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 2 | 2 | 3 | 0 |
| Debt incl. finance leases | — | 2 | 4 | 9 |
| Total assets | — | 57 | 78 | 70 |
| Total liabilities | — | 21 | 38 | 38 |
| Shareholders' equity | 26 | 36 | 40 | 31 |
| Margins and ratios | ||||
| Gross margin | 79.9% | 86.6% | 88.2% | 83.8% |
| Operating margin | 38.9% | 37.7% | 41.4% | −113.7% |
| Net margin | 36.4% | 33.5% | 33.6% | −121.0% |
| Free cash flow margin | −15.4% | −11.6% | −24.8% | −6.2% |
| Rule of 40 (growth + FCF margin) | — | −22.0% | −7.0% | −45.3% |
| Return on capital | — | — | 35.2% | −50.0% |
| Return on equity | — | — | 33.0% | −76.8% |
| Return on assets | — | — | 18.5% | −37.0% |
| Net debt to EBITDA | — | 0.1x | 0.1x | — |